First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bo...
New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting,...
-Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
RIM Smart Labeling is part of IQVIA’s suite of purpose-built regulatory, safety and quality technology solutions and services. Label management is an...
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 45690...
ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body. By measuring the absor...
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the developme...
Saama, a provider of AI- and ML-based solutions that accelerate clinical development and commercialization, announced today the launch of its unified platf...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with canc...
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the F...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
© 2024 Biopharma Boardroom. All Rights Reserved.
